eligibility_summary
Eligible patients: relapsed/refractory multiple myeloma, 3–5 prior therapy lines with prior exposure to proteasome inhibitor, anti‑CD38 mAb, and IMiD, ECOG performance status ≤2, must be ABBV‑383–naïve. Key exclusion: prior treatment with a BCMA×CD3 bispecific antibody.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: ABBV-383, a bispecific T-cell–engaging monoclonal antibody (immunotherapy) given subcutaneously and intravenously (dose-finding plus SC expansion). Mechanism of action: ABBV-383 simultaneously binds BCMA on malignant plasma cells and CD3 on T cells, forming an immune synapse that redirects and activates cytotoxic T cells to kill BCMA-positive myeloma cells, this triggers TCR/CD3 signaling, T-cell proliferation, cytokine release, and perforin/granzyme-mediated apoptosis of target cells. Targets: BCMA-expressing multiple myeloma plasma cells in bone marrow, CD3 on T lymphocytes. Population: relapsed/refractory MM after PI, IMiD, and anti-CD38, excludes prior BCMA×CD3. Primary focus: safety and PK.